共 50 条
- [21] COST-EFFECTIVENESS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) VERSUS BORTEZOMIB PLUS MELPHALAN AND PREDNISONE (VMP)HAEMATOLOGICA, 2014, 99 : 379 - 379Cavenagh, J. D.Belch, A. R.Hulin, C.Basu, S.White, D.Ervin-Haynes, A.Marek, J.Pelligra, C. G.Guo, S.Binder, G.Monzini, M. S.Facon, T.
- [22] MajesTEC-4: Phase 3 trial of Teclistamab plus Lenalidomide versus Lenalidomide in patients with newly diagnosed multiple myelomaBRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 57 - 57Cook, GordonZamagni, ElenaBoccadoro, MarioSpencer, AndrewDelforge, MichelReece, DonnaSzabo, Agoston GyulaEinsele, HermannTerpos, EvangelosSchjesvold, FredrikBila, JelenaDriessen, ChristophBeksac, MeralRodriguez, CesarPei, LixiaShi, YingqiSakabedoyan, CalineJasielec, JagaodaAmin, HimalKobos, RachelSonneveld, PieterVan De Donk, Niels
- [23] Pomalidomide plus Bortezomib plus Low-Dose Dexamethasone Vs Bortezomib plus Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm TrialBLOOD, 2018, 132Dimopoulos, Meletios A.Weisel, KatjaMoreau, PhilippeAnderson, LarryWhite, Darrell J.San-Miguel, Jesus F.Sonneveld, PieterEngelhardt, MonikaJenner, Matthew W.Corso, AlessandroDuerig, JanPavic, MichelSalomo, MortenYu, XinTuong Vi NguyenBensmaine, AminePeluso, TeresaZaki, MohamedRichardson, Paul
- [24] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialLANCET ONCOLOGY, 2021, 22 (12): : 1705 - 1720Gay, FrancescaMusto, PellegrinoRota-Scalabrini, DeliaBertamini, LucaBelotti, AngeloGalli, MonicaOffidani, MassimoZamagni, ElenaLedda, AntonioGrasso, MariellaBallanti, StelvioSpadano, AntonioCea, MichelePatriarca, FrancescaD'Agostino, MattiaCapra, AndreaGiuliani, Nicolade Fabritiis, PaoloAquino, SaraPalmas, AngeloGamberi, BarbaraZambello, RenatoPetrucci, Maria TeresaCorradini, PaoloCavo, MicheleBoccadoro, Mario
- [25] Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaBLOOD, 2019, 134Kapoor, PrashantGertz, Morie A.Laplant, BetsyMalave, Gabriella C.Wolfe, EricMuchtar, EliSiddiqui, Mustaqeem A.Gonsalves, Wilson I.Emanuel, Angie R.Kourelis, TaxiarchisWarsame, RahmaDingli, DavidBuadi, Francis K.Hayman, Suzanne R.Leung, NelsonHwa, Yi L.Hobbs, Miriam A.Fonder, AmieDispenzieri, AngelaLacy, Martha Q.Rajkumar, S. VincentKumar, Shaji K.
- [26] Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideHAEMATOLOGICA, 2015, 100 (06) : 826 - 833Delforge, MichelMinuk, LeonardEisenmann, Jean-ClaudeArnulf, BertrandCanepa, LetiziaFragasso, AlbertoLeyvraz, SergeLanger, ChristianEzaydi, YousefVogl, Dan T.Giraldo-Castellano, PilarYoon, Sung-SooZarnitsky, CharlesEscoffre-Barbe, MartineLemieux, BernardSong, KevinBahlis, Nizar JacquesGuo, ShienMonzini, Mara SilvaErvin-Haynes, AnnetteHouck, VanessaFacon, Thierry
- [27] A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First TrialBLOOD, 2015, 126 (23)Facon, ThierryHulin, CyrilleDimopoulos, Meletios A.Belch, AndrewMeuleman, NathalieMohty, MohamadChen, Wen-MingKim, KihyunZamagni, ElenaRodriguez-Otero, PaulaRenwick, WilliamRose, ChristianTempescul, AdrianPalumbo, AntonioGuo, ShienSturniolo, MichaelErvin-Haynes, AnnetteFermand, Jean-Paul
- [28] Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myelomaAMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (01) : 62 - 67Baz, Rachid C.Shain, Kenneth H.Hussein, Mohamad A.Lee, Ji-HyunSullivan, Daniel M.Oliver, Elizabeth FinleyNardelli, Lisa A.Nodzon, Lisa A.Zhao, XiuhuaOchoa-Bayona, Jose LeonelNishihori, TaigaDalton, William S.Alsina, Melissa
- [29] Short-course lenalidomide plus low-dose dexamethasone in the treatment of newly diagnosed multiple myeloma-single-centre pragmatic studyCURRENT ONCOLOGY, 2017, 24 (05) : E361 - E367Jose, W. M.Pavithran, K.Ganesan, T. S.